Vyznova Corneal Endothelial Cell Injection: Complete Day-of-Surgery Guide & Why 3-Hour Prone Positioning Matters

If you or a family member is scheduled for Vyznova corneal endothelial cell injection therapy, knowing what happens on surgery day — from the moment you arrive to the critical three-hour face-down positioning period — can transform anxiety into confidence. This guide provides a comprehensive, clinically grounded walkthrough of the entire procedure, explains the rationale behind prone positioning, and answers the questions patients ask most. By the end, you will understand not just what to do, but why each step matters for the long-term success of your treatment.

What to Expect on Surgery Day: Vyznova Injection Timeline

Surgery day for Vyznova therapy is structured and predictable. Most patients spend five to six hours at the clinic, from check-in to discharge. Understanding the timeline in advance helps you plan transportation, coordinate your companion's schedule, and arrive with peace of mind.

Pre-Operative Preparation (0–30 Minutes Before Injection)

Upon arrival, a nursing team member will confirm your identity, verify your consent documentation, and review any changes in your medical history or current medications since your last preoperative visit. This step is not administrative formality — certain anticoagulants, immunosuppressants, or NSAIDs can influence intraocular pressure or post-procedural healing, and the surgical team needs the most current information.

You will then be escorted to a preparation area where the following occurs in sequence:

Topical anesthetic eye drops are instilled into the operative eye approximately 15 to 20 minutes before the procedure begins. Most centers use proparacaine hydrochloride (0.5%), lidocaine, or tetracaine, both of which produce reliable surface anesthesia within two to three minutes and last 20 to 30 minutes. You may feel a brief, mild stinging sensation that resolves almost immediately, followed by a comfortable numbness on the ocular surface.

Pupillary constriction is induced using pharmacological drops. The Vyznova injection protocol requires a miotic agent to constrict the pupil, which minimizes the risk of cells inadvertently migrating into the vitreous cavity.

Povidone-iodine antisepsis is applied to the periocular skin and conjunctival fornices using a 5% betadine solution. This step reduces the bacterial load around the eye to near-zero, minimizing endophthalmitis risk — a rare but serious complication of any intraocular procedure.

Vital sign confirmation and a brief neurological orientation check may be performed. Because Vyznova injection is typically performed under topical anesthesia without sedation, confirming that you are alert, cooperative, and able to follow instructions (particularly "look up," "look left," "hold still") is clinically important.

You will be positioned in a reclining ophthalmic chair or a flat surgical bed. A sterile drape will be placed over your face, with a fenestration (opening) exposing only the operative eye. A lid speculum — a small, spring-loaded instrument — will gently hold your eyelids open throughout the procedure, preventing involuntary blinking.

At this point, many patients report that what they feared would be uncomfortable is far more manageable than expected. The anesthetic is effective, the speculum holds the lids without pain.

The Injection Procedure: Step-by-Step Breakdown

The Vyznova injection procedure is well-structured. Here is what occurs, in the order it happens:

Step 1 — Microincision creation. Using a calibrated ophthalmic blade, the surgeon creates a small paracentesis at the limbus (the junction of the cornea and sclera). This incision is typically 0.8mm to 1.0mm in width and is angled to be architecturally self-sealing under normal intraocular pressure.

Step 2 — Endothelial Scraping. A silicon tip micro cannula tapered needle/cannula is introduced into the anterior chamber through the paracentesis. While maintaining the depth and structural integrity of the chamber via continuous BSS (balanced salt solution) infusion, the surgeon gently performs a mechanical scraping of the central corneal posterior surface (typically within an 8.0 to 9.0 mm diameter). This critical maneuver debrides degenerated host endothelial cells and pathological extracellular matrix, thereby creating a pristine "niche" for the donor cells to achieve direct adhesion to Descemet’s membrane. Concurrently, the continuous irrigation facilitates the complete evacuation of inflammatory debris and cellular fragments, ensuring an optimal microenvironment for the subsequent cell injection.

Step 3 — Cell suspension injection. The surgeon uses a small-gauge needle to slowly and steadily inject the Vyznova cell suspension—a precisely measured volume containing a standardized concentration of cultured human corneal endothelial cells (CECs)—into the anterior chamber.

Step 4 — Incision sealing. Although the incision is designed to be self-sealing, a single 10-0 nylon suture is typically placed as a precaution. To confirm a secure closure, the surgeon may apply gentle pressure at the wound site using a sterile cotton-tipped applicator.

Step 5 — Antibiotic and steroid instillation. Topical antibiotic drops and a corticosteroid drop are instilled immediately after the incision is confirmed sealed.

Step 6 — Positioning initiation. This is the moment where your active role in the procedure begins. You will be guided into the prone (face-down) position. The surgical team will confirm you are comfortable and safe, then begin the three-hour cell adhesion window.

Throughout the injection, you will see light, possibly some shadows or fluid movement, but you will not see the surgical instruments inside your eye. Many patients describe the visual experience as looking through water. There is no sharp pain — though a sense of pressure or movement is normal and expected.

Immediate Post-Procedure Monitoring (First 30 Minutes)

While you are in the prone position, having a family member or companion present is beneficial to help ensure you maintain the correct posture. Medical staff will also check on you periodically to provide care. They will confirm your positioning is correct, assess your comfort level, and ensure there are no early adverse signs, such as excessive pain, nausea, or sudden vision changes.

Why Face Down for 3 Hours? The Science of Cell Adhesion After Eye Injection

The requirement to remain prone (face-down) for three hours is often the most challenging part of Vyznova therapy. However, it is a vital step dictated by physics and biology to ensure the treatment’s success.

Gravity-Assisted Positioning (The Physics)

Once injected, Vyznova cells are suspended in the fluid of the eye (aqueous humor). At this stage, they are not yet attached to anything. To clear a cloudy cornea, these cells must settle on its inner surface (the posterior cornea).

By lying face-down, you make the cornea the "floor" of the eye's anterior chamber. Gravity then naturally guides the injected cells downward, ensuring they land precisely where they are needed. If you were to sit up or lie on your back, gravity would pull the cells away from the cornea, causing them to settle on the iris or lens where they cannot function.

The 3-Hour Window (The Biology)

Cell adhesion is a biological process that takes time. The three-hour window is based on clinical evidence showing how long it takes for these specific cells to "take root."

While permanent integration continues for weeks, the three-hour mark is the critical threshold. After this point, the cells are secure enough to resist being dislodged by normal eye movements or fluid circulation.

After the 3-Hour Prone Position: Post-Procedure Care Instructions

Once the three-hour prone positioning period is complete and your surgical team has confirmed your initial post-procedure status, you enter the recovery and monitoring phase.

First 24 Hours: Activity Restrictions & Eye Protection

For the remainder of surgery day and the first 24 hours post-procedure, the following restrictions apply:

No rubbing the eye. The microincision, though self-sealing, is not fully healed at 24 hours. Rubbing creates mechanical distortion of the anterior chamber and can displace adherent cells that have not yet achieved fully stable adhesion. 

No strenuous activity. Activities that significantly elevate systemic blood pressure — heavy lifting, intense aerobic exercise, bending from the waist with the head lower than the heart — can transiently increase intraocular pressure and intraocular fluid dynamics. These changes are modest but potentially sufficient to mechanically stress newly adhering cells.

Medication Schedule: Anti-Inflammatory & Antibiotic Drops

The post-procedure medication regimen serves two purposes: preventing infection and controlling the inflammatory response that any intraocular procedure generates. Your specific regimen will be prescribed by your surgeon, but standard protocols generally include:

Topical antibiotic drops: Typically administered four times daily for the first one to several months post-procedure. These prevent bacterial colonization of the ocular surface and any residual wound site.

Topical corticosteroid drops: Typically administered four times daily initially, then tapered gradually over four to six weeks. In some cases, treatment may continue for up to a year. Corticosteroids suppress the intraocular inflammatory response—a normal but potentially damaging biological reaction to the introduction of foreign material (including the cell suspension) into the anterior chamber. Uncontrolled inflammation can damage newly adhered cells.

IOP-lowering agents may be added if intraocular pressure monitoring shows elevated pressure during follow-up visits. Do not discontinue any prescribed eye drop without explicit guidance from your surgical team, even if your eye feels comfortable.

Follow-Up Monitoring

Post-procedure follow-up visits are structured to capture the most diagnostically important time points in the cell engraftment and corneal recovery process:

Day 0–1 (24 Hours): Initial cell engraftment may be observed via imaging immediately following the procedure.

Week 1 (Day 2–7): During this first week, the primary focus is monitoring for early complications, such as infection or inflammation. If you successfully clear this initial phase without complications, you may discuss the possibility of returning to your home country. In this case, seamless coordination between your surgical team and your local ophthalmologist is essential for ongoing monitoring.

Month 1 (Week 4): The most clinically significant early milestone. By four weeks, cell adhesion and initial engraftment should be substantially complete. Specular microscopy at this visit provides a reliable early measure of therapeutic success. It is important to note that visual acuity typically takes about four weeks to show noticeable improvement as the corneal edema (swelling) gradually resolves.

Month 3 and Beyond: By the third month, visual acuity generally begins to reach a stable plateau, though this can vary depending on your specific underlying condition. Follow-up visits focus on confirming the durability of the cell engraftment and monitoring for any late-stage adverse effects. Your doctor will monitor for potential side effects of corticosteroid use (such as increased eye pressure) and continue to optimize your medication taper based on your eye’s progress.

Conclusion

Vyznova corneal endothelial cell injection represents one of the most exciting advances in corneal medicine in a generation — offering patients with endothelial cell loss a minimally invasive alternative to conventional transplant surgery.

The three-hour prone positioning period is the centerpiece of your active participation in this therapy's success. It is a biologically precise intervention using physics to assist your own cells (or, more precisely, the cells being given to you) in finding their home.

If at any point during your recovery you are uncertain whether what you are experiencing is expected, contact your surgical center. No question is too small when it concerns your vision.

About the Author

Shigeto Shimmura, MD, PhD

Director, Fujita Health University Haneda Clinic

Professor and Chair, Department of Clinical Regenerative Medicine, Fujita Health University

View more